Exploiting Deficiencies in the Tumor Genome: Expert Perspectives in the Era of PARP Inhibitors

Activity Details
  • Credit Amounts:
  • Cost: Free
  • Release: May 31, 2019
  • Expires: May 31, 2020
  • Average User Rating:
    ( Ratings)

To complete activity please click below

Click Here

 

Faculty

Ursula A.  Matulonis Ursula A. Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Bradley J.  Monk Bradley J. Monk, MD, FACS, FACOG
Professor
Arizona Oncology (US Oncology Network)
US Oncology Medical Director of Gynecologic Oncology Research
University of Arizona College of Medicine–Phoenix
Creighton University School of Medicine at St. Joseph’s Hospital
Phoenix, Arizona

Kathleen N.  Moore Kathleen N. Moore, MD, MS
Oklahoma City, Oklahoma

Needs Statement

Attendees of this symposium will gain an appreciation of the genes involved in DNA damage response (DDR) pathways and their role in tumorigenesis; the latest advances to clinically target the DDR, including the use of poly-ADP ribose polymerase (PARP) inhibitors; and the most recent updates in genetic testing and counseling guidelines. 

Target Audience

This activity was developed for gynecologic oncologists, medical oncologists, pathologists, nurses, nurse practitioners, physician assistants, pharmacists, and all other allied health professionals of the gynecologic oncology team.

Objectives

Upon completion of this activity, participants will be able to:

1. Describe the latest advances in the understanding of molecular features of tumors with “BRCAness” or BRCA1/2 mutations and the rationale for the use of PARP inhibitors in these tumors.

2. Assess current and evolving data on the safety and efficacy of PARP inhibitors in ovarian cancer with BRCA1/2 and other DNA damage response (DDR)-related mutations.

3. Examine the role of recommended genetic testing and counseling in patients with possible deleterious mutations in the DDR pathway and its implications on treatment decisions and patient outcomes.

4. Discuss top clinical questions and patient cases pertaining to the treatment and management of advanced ovarian cancer patients with BRCA1/2 or other DDR-related mutations.